These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18706774)

  • 21. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
    Wu LT; Woody GE; Yang C; Blazer DG
    J Addict Med; 2011 Mar; 5(1):28-35. PubMed ID: 21532972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use.
    Metz VE; Brown QL; Martins SS; Palamar JJ
    Drug Alcohol Depend; 2018 Feb; 183():261-266. PubMed ID: 29310077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An exploratory study of OxyContin use among individuals with substance use disorders.
    Levy MS
    J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
    Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discrepancies in prevalence estimates in two national surveys for nonmedical use of a specific opioid product versus any prescription pain reliever.
    Biondo G; Chilcoat HD
    Drug Alcohol Depend; 2014 Jan; 134():396-400. PubMed ID: 24210422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.
    Paljarvi T; Strang J; Quinn PD; Luciano S; Fazel S
    Addiction; 2021 Sep; 116(9):2409-2415. PubMed ID: 33394528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The characteristics of a cohort who tamper with prescribed and diverted opioid medications.
    Larance B; Lintzeris N; Bruno R; Peacock A; Cama E; Ali R; Kihas I; Hordern A; White N; Degenhardt L
    J Subst Abuse Treat; 2015 Nov; 58():51-61. PubMed ID: 26286818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early OxyContin Marketing Linked To Long-Term Spread Of Infectious Diseases Associated With Injection Drug Use.
    Dennett JM; Gonsalves GS
    Health Aff (Millwood); 2023 Aug; 42(8):1081-1090. PubMed ID: 37467441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review.
    Lalic S; Jokanovic N; Ilomäki J; Gisev N; Lloyd B; Lubman DI; Bell JS
    Res Social Adm Pharm; 2019 Aug; 15(8):925-935. PubMed ID: 30076092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study.
    Karamouzian M; Buxton JA; Hategeka C; Nosova E; Hayashi K; Milloy MJ; Kerr T
    Int J Drug Policy; 2022 Nov; 109():103852. PubMed ID: 36122483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription opioid misuse and comorbid substance use: Past 30-day prevalence, correlates and co-occurring behavioral indicators in the 2016 National Survey on Drug Use and Health.
    Grigsby TJ; Howard JT
    Am J Addict; 2019 Feb; 28(2):111-118. PubMed ID: 30701620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The release of abuse-deterrent OxyContin and adolescent heroin use.
    DiNardi M
    Drug Alcohol Depend; 2021 Dec; 229(Pt B):109114. PubMed ID: 34638038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States.
    Cicero TJ; Ellis MS; Surratt HL; Kurtz SP
    Pain; 2013 Dec; 154(12):2639-2648. PubMed ID: 24287106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010.
    Jones CM
    Drug Alcohol Depend; 2013 Sep; 132(1-2):95-100. PubMed ID: 23410617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical correlates of prescription opioid analgesic use in pregnancy.
    Smith MV; Costello D; Yonkers KA
    Matern Child Health J; 2015 Mar; 19(3):548-56. PubMed ID: 24951127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.